Showing 3701-3710 of 5646 results for "".
- Claes H. Dohlman, MD, Cornea Research Pioneer and Visionary, Passes Away at 101https://modernod.com/news/claes-h-dohlman-md-cornea-research-pioneer-and-visionary-passes-away-at-101/2482356/Cornea Research Pioneer Claes H. Dohlman, MD, PhD, professor of Ophthalmology, Emeritus, and former Chief and Chair of the Department of Ophthalmology at Mass Eye and Ear and Harvard Medical School (HMS), passed away at the age of 101 on July 14, 2024, Mass Eye and Ear announced on Monday.
- Genentech to Reintroduce Susvimo Ocular Implant for Wet AMDhttps://modernod.com/news/genentech-to-reintroduce-susvimo-for-wet-amd/2482347/Following the end of a voluntary recall, Genentech said it is reintroducing Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of wet age-related macular degeneration (AMD). The decision c
- PharmAbcine Advances Phase 1 Clinical Trial of PMC-403 for nAMDhttps://modernod.com/news/pharmabcine-advances-phase-1-clinical-trial-of-pmc-403-for-namd/2482343/PharmAbcine, Inc., a South Korea-based clinical-stage developer of medical therapeutics, announced the Safety Review Committee (SRC) approval of single 3-mg dose for the third cohort in phase 1 clinical trial of PMC-403, the company&rsquo
- FDA Approves Genentech’s Vabysmo Prefilled Syringe for AMD, DME, and RVOhttps://modernod.com/news/genentechs-vabysmo-prefilled-syringe-approved-by-fda-for-amd-dme-and-rvo/2482342/Genentech announced FDA approval of Vabysmo (faricimab-svoa) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema after retinal vein occlusion (RVO). The company advised that Vabysmo
- NEI Funded Study Reveals Neural Mechanism of Encoding Familiar Faceshttps://modernod.com/news/nei-funded-study-reveals-neural-mechanism-of-encoding-familiar-faces/2482335/National Eye Institute funded research at University of Tsukuba demonstrated that faces of familiar individuals with whom one has frequent social interactions with are learned in the basal ganglia region through the same neural mechanisms that recognize the value of objects.
- Rayner Closes Recruitment for IDE for RayOne EMV Toric IOLshttps://modernod.com/news/rayner-closes-recruitment-for-ide-for-rayone-emv-toric-iols/2482332/Rayner announced that it has closed recruitment in the investigational device exemption (IDE) study for its EMV Toric IOL in the US. The study will ultimately enable the introduction of the RayOne EMV Toric lens for use in the US. Developed in collaboration with Professor
- FDA Clears Alcon's Unity Vitreoretinal-Cataract System and Standalone Cataract Systemhttps://modernod.com/news/fda-clears-alcons-unity-vitreoretinal-cataract-system-and-unity-standalone-cataract-system/2482329/Alcon announced that its Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) have received FDA 510(k) clearance. The new devices are the first to be introduced from Alcon’s Unity portfolio and represent Alcon's next generation of e
- Ocugen Doses First Patient in Phase 3 Clinical Trial for OCU400 Gene Therapy for RPhttps://modernod.com/news/ocugen-doses-first-patient-in-phase-3-clinical-trial-for-ocu400-gene-therapy-for-retinitis-pigmentosa/2482326/Ocugen announced that the first patient has been dosed in its phase 3 liMeliGhT clinical trial for OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). “Each clinical milestone achieved by OCU400 brings us closer to providing a one-
- Neurotech Receives Priority Review of BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)https://modernod.com/news/neurotech-receives-priority-review-of-biologics-license-application-bla-for-nt-501-as-a-treatment-for-macular-telangiectasia-type-2-mactel/2482324/The FDA has granted priority review of Neurotech Pharmaceuticals's biologic license application (BLA) for NT-501 (revakinagene taroretcel), an investigational encapsulated cell therapy for the treatment of Macular Telangiectasia Type 2 (MacTel). The designation m
- J&J's Nipocalimab Significantly Improves Sjögren’s Disease Activity in a Phase 2 Studyhttps://modernod.com/news/jjs-nipocalimab-significantly-improves-sjogrens-disease-activity-in-a-phase-2-study/2482323/Johnson & Johnson announced that patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa score versus placebo at 24 weeks compared to baseline (primary endpoint) in the phase 2 DAHLIAS dose-rang